BackgroundImmune checkpoint blocker (ICB) has shown significant clinical activity in melanoma. However, there are no clinically approved biomarkers to aid patient selection. We aimed to identify patie
1. Type III biliary atresia refers to the discontinuity of both right and left hepatic ducts to the level of the porta hepatis. Unfortunately, type III BA is common, accounting for >90% of cases. *at
